1-6 of 6
Rashmi Malla
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Patrick K Reville, Hagop Kantarjian, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Koji Sasaki, Nicholas Short, Ghayas C. Issa, Maro Ohanian, Elias Jabbour, Guillermo Montalban-Bravo, Abhishek Maiti, Nitin Jain, Alessandra Ferrajoli, Kapil N. Bhalla, Koichi Takahashi, Caitlin R. Rausch, Danielle Hammond, Rashmi Malla, Kelly Quagliato, Mark Brandt, Uday R Popat, Marina Konopleva, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2022) 140 (Supplement 1): 9041–9043.
https://doi.org/10.1182/blood-2022-168029
Published: 2022
Journal Articles

Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Patrick K Reville, Hagop Kantarjian, Gautam Borthakur, Naveen Pemmaraju, Courtney D. DiNardo, Koji Sasaki, Naval Daver, Ghayas C. Issa, Maro Ohanian, Guillermo Montalban-Bravo, Nicholas J. Short, Nitin Jain, Kapil N. Bhalla, Elias J. Jabbour, Alessandra Ferrajoli, Koichi Takahashi, Caitlin R. Rausch, Rashmi Malla, Kelly Marek, Mark Brandt, Uday R. Popat, Michael Andreeff, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia
Journal: Blood
Blood (2021) 138 (Supplement 1): 367.
https://doi.org/10.1182/blood-2021-147360
Published: 2021
Journal Articles

Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials

Sangeetha Venugopal, Elias J. Jabbour, Naveen Pemmaraju, Guillermo Montalban-Bravo, Kelly S. Chien, Naval Daver, Nitin Jain, Jan A. Burger, Yesid Alvarado, Abhishek Maiti, Courtney D. DiNardo, Gautam Borthakur, Rashmi Malla, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia
Journal: Blood
Blood (2021) 138 (Supplement 1): 4420.
https://doi.org/10.1182/blood-2021-153044
Published: 2021
Journal Articles

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koji Sasaki, MD, Ghayas C. Issa, MD, Maro Ohanian, DO, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Kapil N. Bhalla, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Koichi Takahashi, MD PhD, Rashmi Malla, RN, BSN, Kelly Marek, Mark Brandt, BS, Uday R. Popat, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
https://doi.org/10.1182/blood-2020-142092
Published: 2020
Journal Articles

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Jorge E. Cortes, MD, Marina Y Konopleva, MD PhD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Guillermo Montalban Bravo, MD, Ghayas C. Issa, MD, Kiran Naqvi, MDMPH, Nicholas J. Short, MD, Courtney D. DiNardo, MDMSc, Kapil N. Bhalla, MD, Elias Jabbour, MD, Koichi Takahashi, MD, Koji Sasaki, MD, Steven M. Kornblau, MD, Rashmi Malla, RN, BSN, Sherry A. Pierce, BSN, BA, Xuemei Wang, MS, Zeev E. Estrov, MD, Michael Andreeff, MD PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2647.
https://doi.org/10.1182/blood-2019-122477
Published: 2019
Journal Articles

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Christopher B. Benton, MD, William G. Wierda, MD PhD, Prithviraj Bose, MD, Musa E. Yilmaz, MD, Elias J. Jabbour, MD, Steven M. Kornblau, MD, Kapil N. Bhalla, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Rashmi Malla, RN, BSN, Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4057.
https://doi.org/10.1182/blood-2018-99-117334
Published: 2018